Table 4.
Multivariate-Adjusted Odds Ratios (95% Confidence Intervals) for Having HbA1c <7% After Initiating GLP-1 Receptor Agonists Therapy in Type 2 Diabetes Patients.
| Baseline variable | 0-6 months, n = 237 | P value | 7-12 months, n = 278 | P value | 13-18 months, n = 286 | P value |
|---|---|---|---|---|---|---|
| Age (per year) | 0.96 (0.93-0.99) | .0332 | 0.97 (0.94-1.04) | .0862 | 0.98 (0.94-1.12) | .1900 |
| Sex (males) | 0.67 (0.35-1.31) | .2457 | 0.76 (0.37-1.54) | .4385 | 0.90 (0.43-1.89) | .7899 |
| Private health insurance (yes/no) | 1.00 (0.33-3.06) | .9947 | 1.08 (0.33-3.53) | .8944 | 1.25 (0.37-4.25) | .7163 |
| Diabetologist care (yes/no) | 0.76 (0.31-1.86) | .5492 | 0.99 (0.39-2.53) | .9901 | 0.88 (0.33-2.56) | .8060 |
| Baseline HbA1c (%) | 0.46 (0.34-0.62) | <.0001 | 0.40 (0.28-0.57) | <.0001 | 0.37 (0.26-0.55) | <.0001 |
| Obesity diagnosis (yes/no) | 1.47 (0.76-2.83) | .2541 | 1.68 (0.83-3.37) | .1472 | 1.89 (0.90-3.96) | .0915 |
| Nephropathy (yes/no) | 0.84 (0.31-2.31) | .7417 | 0.52 (0.16-1.68) | .2766 | 0.86 (0.26-2.88) | .8070 |
| Peripheral vascular disease (yes/no) | 3.60 (1.04-12.46) | .0430 | 0.99 (0.26-3.83) | .9975 | 1.03 (0.24-4.43) | .9651 |
All models further adjusted for Charlson comorbidity score, coronary heart disease, myocardial infarction, stroke, retinopathy, peripheral neuropathy, hypertension, and hyperlipidemia.